ENVI strengthens case for non-viables as it tackles ethically-controversial issues
This article was originally published in Clinica
The latest draft report put together by Miroslav Mikolasik, rapporteur at the European Parliament's Committee on the Environment Public Health and Food Safety (ENVI), on the European Commission's proposed Advanced Therapies Medicinal Products (ATMP) Regulation, is currently devoid of any of the ethically-controversial issues that caused it to founder when MEPs last voted on the text.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.